Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
tarsus pharmaceuticals 2024年第二季度GAAP每股收益爲$(0.88)，高於$(0.94)的預估值；銷售額爲4081.3萬美元，高於3166.4萬美元的預估值。
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.94) by 6.38 percent. This is a 24.79 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $40.813 million which beat the analyst consensus estimate of $31.664 million by 28.89 percent.
塔蘇斯製藥公司（納斯達克股票代碼：TARS）公佈的季度虧損爲每股0.88美元，比分析師普遍預期的0.94美元（0.94美元）高出6.38％。這比去年同期每股虧損1.17美元（1.17美元）增長了24.79％。該公司公佈的季度銷售額爲4,081.3萬美元，比分析師普遍預期的3166.4萬美元高出28.89％。